Discovery, structural optimization, and anti-tumor bioactivity evaluations of betulinic acid derivatives as a new type of ROR & gamma; antagonists
2023-09-05
发表期刊EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (IF:6.0[JCR-2023],6.1[5-Year])
ISSN0223-5234
EISSN1768-3254
卷号257
发表状态已发表
DOI10.1016/j.ejmech.2023.115472
摘要

Betulinic acid (BA) is a natural pentacyclic triterpenoid that has a wide range of biological and pharmacological effects. Here, computational methods such as pharmacophore screening and reverse docking were used to predict the potential target for BA. Retinoic acid receptor-related orphan receptor gamma (ROR?) was confirmed as its target by several molecular assays as well as crystal complex structure determination. ROR? has been the focus of metabolic regulation, but its potential role in cancer treatment has only recently come to the fore. In this study, rationale optimization of BA was performed and several new derivatives were generated. Among them, the compound 22 showed stronger binding affinity with ROR? (K-D = 180 nM), good anti-proliferative activity against cancer cell lines, and potent anti-tumor efficacy with a TGI value of 71.6% (at a dose of 15 mg/kg) in the HPAF-II pancreatic cancer xenograft model. Further RNA-seq analysis and cellular validation experiments sup-ported that ROR? antagonism was closely related to the antitumor activity of BA and 22, resulting in suppression of the RAS/MAPK and AKT/mTORC1 pathway and inducing caspase-dependent apoptosis in pancreatic cancer cells. ROR? was highly expressed in cancer cells and tissues and positively correlated with the poor prognosis of cancer patients. These results suggest that BA derivatives are potential ROR? antagonists worthy of further exploration.

关键词Betulinic acid ROR & gamma antagonists Target identification Rationale structure optimization Anti-tumor effects
URL查看原文
收录类别SCI
语种英语
资助项目Major Research Plan of the National Natural Science Foundation of China[91953000] ; Natural Science Foundation of Shanghai[19ZR1467700] ; Lingang Laboratory[
WOS研究方向Pharmacology & Pharmacy
WOS类目Chemistry, Medicinal
WOS记录号WOS:001011955900001
出版者ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
引用统计
正在获取...
文献类型期刊论文
条目标识符https://kms.shanghaitech.edu.cn/handle/2MSLDSTB/316467
专题免疫化学研究所
生命科学与技术学院
免疫化学研究所_特聘教授组_蒋华良组
生命科学与技术学院_硕士生
生命科学与技术学院_博士生
免疫化学研究所_PI研究组_白芳组
共同第一作者Xu, Lansong; Wu, Sanan
通讯作者Zhang, Xianglei; Bai, Fang; Xie, Chengying
作者单位
1.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China
2.Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Dev Ctr, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China
3.Univ Sci & Technol China, Affiliated Hosp USTC 1, Anhui Prov Hosp, Div Life Sci & Med, Hefei, Anhui, Peoples R China
4.Shanghai Tech Univ, Shanghai Inst Adv Immunochem Studies, 393 Middle Huaxia Rd, Shanghai 201210, Peoples R China
5.Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China
6.Chinese Acad Sci, Shanghai Inst Mat Med, China Suzhou Inst Drug Innovat, Suzhou 215123, Jiangsu, Peoples R China
7.Shanghai Clin Res & Trial Ctr, Shanghai 201210, Peoples R China
8.Lingang Lab, Shanghai 200031, Peoples R China
通讯作者单位免疫化学研究所;  生命科学与技术学院
推荐引用方式
GB/T 7714
Mei, Lianghe,Xu, Lansong,Wu, Sanan,et al. Discovery, structural optimization, and anti-tumor bioactivity evaluations of betulinic acid derivatives as a new type of ROR & gamma; antagonists[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,2023,257.
APA Mei, Lianghe.,Xu, Lansong.,Wu, Sanan.,Wang, Yafang.,Xu, Chao.,...&Xie, Chengying.(2023).Discovery, structural optimization, and anti-tumor bioactivity evaluations of betulinic acid derivatives as a new type of ROR & gamma; antagonists.EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,257.
MLA Mei, Lianghe,et al."Discovery, structural optimization, and anti-tumor bioactivity evaluations of betulinic acid derivatives as a new type of ROR & gamma; antagonists".EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 257(2023).
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
个性服务
查看访问统计
谷歌学术
谷歌学术中相似的文章
[Mei, Lianghe]的文章
[Xu, Lansong]的文章
[Wu, Sanan]的文章
百度学术
百度学术中相似的文章
[Mei, Lianghe]的文章
[Xu, Lansong]的文章
[Wu, Sanan]的文章
必应学术
必应学术中相似的文章
[Mei, Lianghe]的文章
[Xu, Lansong]的文章
[Wu, Sanan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。